Andrea C Enzinger1, Baohui Zhang2, Jane C Weeks3, Holly G Prigerson4. 1. Center for Psychosocial Epidemiology and Outcomes Research, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; McGraw/Patterson Center for Population Sciences, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. 2. Center for Psychosocial Epidemiology and Outcomes Research, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; McGraw/Patterson Center for Population Sciences, Dana-Faber Cancer Institute, Boston, Massachusetts, USA. 3. Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; McGraw/Patterson Center for Population Sciences, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. 4. Center for Psychosocial Epidemiology and Outcomes Research, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; McGraw/Patterson Center for Population Sciences, Dana-Faber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. Electronic address: holly_prigerson@dfci.harvard.edu.
Abstract
CONTEXT: Clinical trials are a common therapeutic option for patients with advanced incurable cancer. OBJECTIVES: To examine the associations between trial participation and end-of-life (EOL) outcomes, including aggressive care and quality of life (QOL). METHODS: Coping with Cancer, a multicenter prospective cohort study of patients with metastatic cancer, progressed after at least first-line chemotherapy. Baseline chart review documented clinical trial participation. Baseline interviews assessed psychosocial characteristics and EOL preferences. Caregiver interview and chart review assessed medical care and QOL near death. The primary outcome was aggressive EOL care (ventilation, resuscitation, or intensive care unit admission in last week of life). Propensity score weighting balanced patient characteristics that differed by trial participation, including care preferences and EOL discussion. Propensity score-weighted regression models estimated the effect of trial participation on outcomes. RESULTS: Of 352 patients followed to death, 37 were enrolled in a clinical trial at baseline. In propensity score-weighted analyses, trial participation was significantly associated with aggressive EOL care (21.6% vs. 12.0%, adjusted odds ratio [AOR] 2.04, 95% confidence interval [CI] 1.00-4.15), late hospice enrollment (51.4% vs. 42.2%, AOR 1.96, 95% CI 1.10-3.50), hospital death (48.6% vs. 25.7%, AOR 2.74, 95% CI 1.37-5.47), intensive care unit death (16.2% vs. 6.3%, AOR 3.53, 95% CI 1.29-9.65), and inferior QOL near death (least squares mean 5.93 vs. 7.69, P<0.001). Controlling for EOL care, trial enrollment was no longer associated with QOL near death (P=0.342). CONCLUSION: Clinical trial participation is associated with aggressive EOL care. Aggressive EOL care appears to explain the association between trial participation and QOL near death.
CONTEXT: Clinical trials are a common therapeutic option for patients with advanced incurable cancer. OBJECTIVES: To examine the associations between trial participation and end-of-life (EOL) outcomes, including aggressive care and quality of life (QOL). METHODS: Coping with Cancer, a multicenter prospective cohort study of patients with metastatic cancer, progressed after at least first-line chemotherapy. Baseline chart review documented clinical trial participation. Baseline interviews assessed psychosocial characteristics and EOL preferences. Caregiver interview and chart review assessed medical care and QOL near death. The primary outcome was aggressive EOL care (ventilation, resuscitation, or intensive care unit admission in last week of life). Propensity score weighting balanced patient characteristics that differed by trial participation, including care preferences and EOL discussion. Propensity score-weighted regression models estimated the effect of trial participation on outcomes. RESULTS: Of 352 patients followed to death, 37 were enrolled in a clinical trial at baseline. In propensity score-weighted analyses, trial participation was significantly associated with aggressive EOL care (21.6% vs. 12.0%, adjusted odds ratio [AOR] 2.04, 95% confidence interval [CI] 1.00-4.15), late hospice enrollment (51.4% vs. 42.2%, AOR 1.96, 95% CI 1.10-3.50), hospital death (48.6% vs. 25.7%, AOR 2.74, 95% CI 1.37-5.47), intensive care unit death (16.2% vs. 6.3%, AOR 3.53, 95% CI 1.29-9.65), and inferior QOL near death (least squares mean 5.93 vs. 7.69, P<0.001). Controlling for EOL care, trial enrollment was no longer associated with QOL near death (P=0.342). CONCLUSION: Clinical trial participation is associated with aggressive EOL care. Aggressive EOL care appears to explain the association between trial participation and QOL near death.
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Eli L Diamond; Katherine S Panageas; Alexis Dallara; Ariel Pollock; Allison J Applebaum; Alan C Carver; Elena Pentsova; Lisa M DeAngelis; Holly G Prigerson Journal: J Pain Symptom Manage Date: 2016-11-01 Impact factor: 3.612
Authors: Ravi B Parikh; Eun Jeong Min; E Paul Wileyto; Fauzia Riaz; Cary P Gross; Roger B Cohen; Rebecca A Hubbard; Qi Long; Ronac Mamtani Journal: JAMA Oncol Date: 2021-12-01 Impact factor: 31.777
Authors: Eli L Diamond; David Russell; Maria Kryza-Lacombe; Kathryn H Bowles; Allison J Applebaum; Jeanne Dennis; Lisa M DeAngelis; Holly G Prigerson Journal: Neuro Oncol Date: 2015-08-09 Impact factor: 12.300
Authors: Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton Journal: J Pain Symptom Manage Date: 2019-10-19 Impact factor: 3.612
Authors: Victor Wei-Che Shen; Che Yang; Li-Ling Lai; Ying-Ju Chen; Hsien-Hao Huang; Shih-Hung Tsai; Teh-Fu Hsu; David Hung-Tsang Yen Journal: Int J Environ Res Public Health Date: 2021-06-10 Impact factor: 3.390